Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Coronavirus Panel Draws Up Plan for Vaccination System, Priority
The government’s panel on the novel coronavirus on December 23 proposed a vaccination system and priority plan, calling for a simple and efficient immunization program with no cost burdens on municipalities. After taking public comments, it hopes to finalize the…
To read the full story
Related Article
- Japan to Prioritize COVID-19 Vaccinations for Doctors, Staffers in Frequent Contact with Infected Patients
December 15, 2020
- Coronavirus Panel OKs Interim Report on COVID-19 Vaccination, Sorts Out Roles of Central, Local Govts
September 29, 2020
- Medical Professionals to Be Prioritized in COVID-19 Vaccination: Govt Panel
September 8, 2020
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…